Preapproval Inspection and Submission to the FDA
About the Course
Preapproval inspections conducted by the U.S. Food and Drug Administration directly influence whether NDA, ANDA, and PMA applications progress toward approval or face delays, observations, or rejection. Manufacturing controls, testing practices, documentation accuracy, validation status, and facility conditions are closely reviewed to determine whether products are consistently produced in accordance with current Good Manufacturing Practices and applicable regulatory requirements. Weak inspection preparation frequently exposes gaps in quality systems, establishment records, and process controls that can affect approval timelines and post-submission actions.
This webinar addresses the operational and regulatory expectations associated with FDA preapproval inspections for pharmaceutical and medical device products. Particular attention is given to inspection focus areas under 21 CFR 210/211 and 21 CFR 820, including personnel practices, equipment readiness, establishment file reviews, process validation, and handling FDA inquiries. The course also examines inspection risk factors, material rejection concerns, pharmacovigilance considerations, and documentation practices supporting submission credibility.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Commonly Asked Questions About This Subject
How can a facility justify manufacturing changes made after submission but before a preapproval inspection?
Changes made after submission receive careful scrutiny because inspectors want assurance that the application still reflects the commercial manufacturing process. A change is easier to defend when the supporting rationale, risk assessment, and implementation records are complete before the inspection begins.
Change control documentation should explain why the modification was necessary, what product quality risks were evaluated, and whether additional validation or regulatory reporting was required. Technical conclusions should be supported by objective data rather than assumptions.
Inspectors frequently compare batch records, validation reports, procedures, equipment documentation, and quality records to determine whether the change was consistently implemented. Conflicting documentation often generates more concern than the change itself.
A defensible change demonstrates continuity. The supporting records should show that product quality, process performance, and regulatory commitments remained under control throughout implementation, leaving little room for uncertainty during inspection.
Why do FDA inspectors spend considerable time reviewing historical deviations during a preapproval inspection?
Historical deviations provide insight into how quality decisions are made when unexpected events occur. Inspectors review investigation records to determine whether problems were understood, corrected, and prevented from recurring through an effective quality system.
Repeated deviations involving the same equipment, manufacturing step, analytical method, or environmental condition often receive additional attention. Similar investigations with repeated conclusions can indicate that underlying process weaknesses remain unresolved.
The supporting evidence behind each investigation carries significant weight. Root cause analyses should align with production data, laboratory findings, maintenance records, and documented technical evaluations instead of relying on speculation.
Inspection confidence increases when historical records demonstrate consistent investigation practices and measurable corrective actions. Well documented improvements are more persuasive than repeatedly closing deviations without showing sustained operational control.
Which documentation weaknesses are most difficult to defend during a preapproval inspection?
Documentation becomes difficult to defend when records describing the same activity are inconsistent or incomplete. Inspectors compare procedures, batch records, validation reports, laboratory documentation, and electronic records to verify that they accurately reflect routine operations.
Technical decisions should be traceable throughout the quality system. Changes to specifications, process parameters, sampling plans, or investigation conclusions should include documented scientific justification that can withstand detailed review.
Timing also influences credibility. Records completed well after manufacturing activities, unexplained corrections, missing approvals, or conflicting revision histories can raise questions about data reliability and document control practices.
Documentation should provide a complete and consistent account of what occurred and why decisions were made. Records created during normal operations and supported by objective evidence are considerably easier to defend than explanations reconstructed during an inspection.
How do FDA inspectors distinguish between isolated quality issues and evidence of a weak quality system?
Inspectors rarely judge a quality system based on a single deviation or isolated inspection observation. Their assessment focuses on whether similar issues appear repeatedly across manufacturing, laboratory, engineering, validation, and quality records.
Patterns often reveal more than individual events. Recurring equipment failures, repeated investigation extensions, similar CAPA findings, or ongoing documentation deficiencies suggest that systemic controls are not functioning effectively despite individual corrective actions.
Inspectors also evaluate management responses to emerging trends. Quality metrics, internal audit findings, management review records, and effectiveness checks help demonstrate whether recurring issues were recognized, investigated, and resolved before they affected product quality.
A strong quality system consistently identifies, evaluates, and eliminates recurring risks through documented action. When evidence shows sustained improvement instead of repeated short term fixes, inspectors are more likely to view isolated issues as exceptions rather than indicators of broader system weakness.
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


